Virulizin

Drug Profile

Virulizin

Alternative Names: Virulizin

Latest Information Update: 04 Jun 2015

Price : $50

At a glance

  • Originator Lorus Therapeutics
  • Developer Aptose Biosciences
  • Class Antineoplastics
  • Mechanism of Action Interleukin 17 stimulants; Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Discontinued Breast cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Kaposi's sarcoma; Lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Uterine cancer

Most Recent Events

  • 04 Jun 2015 Discontinued - Phase-III for Pancreatic cancer in USA, Brazil, Canada, Czech Republic, Hungary, Mexico, Poland, Romania, Russia, Spain and Ukraine (IM)
  • 02 Sep 2014 Lorus Therapeutics is now called Aptose Biosciences
  • 08 Apr 2008 Virulizin® licensed to ZOR Pharmaceuticals in Central, North and South America, Europe and Israel for the treatment of pancreatic cancer and other human therapeutic applications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top